Bexarotene
Retinoid
DB00307
Approved Indication
Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent di
3
Targets
0
Resistance Mutations
6
References
3H0A
Structure Loaded
Protein Targets
Mechanism of Action
Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR<sub>α</sub>, RXR<sub>β</sub>, RXR<sub>γ</sub>. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.
Details
DrugBank ID
DB00307 ↗
Approval Date
1999-12-29
Molecular Weight
348.4779 g/mol
Drug Class
Retinoid
ATC Codes
L01XX25
Synonyms
Bexaroten, Bexarotène, Bexarotene
PubChem
CID: 82146 ↗
ChEMBL
CHEMBL1023 ↗
SMILES
CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C
ADMET Profile
Computing properties…
Drug References (DrugBank)